Navigation Links
Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
Date:5/16/2012

ational compound.  Afatinib is not approved by the FDA; its safety and efficacy have not been established. 

Afatinib is an investigational oral, once-daily irreversible ErbB Family Blocker that specifically inhibits epidermal growth factor receptor (EGFR or ErbB1), human epidermal receptor 2 (HER2 or ErbB2), ErbB3 and ErbB4.  It is currently in phase III clinical development in NSCLC, head and neck and breast cancer. 

About the Afatinib Clinical Trial Program in Advanced NSCLCThe LUX-Lung studies evaluate the use of afatinib in various settings of advanced NSCLC, including in patients harboring EGFR mutations and those with recurrent disease.  These trials include:

  • LUX-Lung 1, a Phase IIb/III trial investigating afatinib plus best supportive care (BSC) versus placebo plus BSC in NSCLC patients who were previously treated with first-line chemotherapy and the reversible EGFR TKIs erlotinib or gefitinib.
  • LUX-Lung 2, a Phase II trial evaluating afatinib in NSCLC patients with EGFR mutations (EGFR M+), either treatment-naive or after one line of treatment with chemotherapy.
  • LUX-Lung 3, a Phase III trial investigating afatinib as a first-line treatment in patients with advanced NSCLC with EGFR mutations. 
  • LUX-Lung 4, a Phase I/II trial of afatinib in NSCLC patients who have progressed after conventional EGFR-TKI treatment. 
  • LUX-Lung 5, a global Phase III trial in patients previously treated with erlotinib or gefitinib. This is the first randomized Phase III trial investigating whether patients who initially benefit from treatment with afatinib alone may further benefit from afatinib beyond progression when given in combination with chemotherapy.
  • LUX-Lung 6, a Phase III trial investigating the efficacy and safety of afatinib compared to standard chemotherapy for first-line treatment of NSCLC patients with EGFR mutations.
  • LUX-Lung 7, a Phase IIb trial e
    '/>"/>

  • SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
    2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
    3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
    4. Boehringer Ingelheim Unveils Diabetes Pipeline
    5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
    6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
    7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
    8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
    9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
    10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
    11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ... Drew Young has joined the company as Senior ... will be responsible for leading the strategic direction of ... Bringing more than 20 years of experience ... pharmaceutical and biotech companies, Mr. Young comes to EMD ...
    (Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
    (Date:9/2/2014)... Mass. , Sept. 2, 2014  Hologic, Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Morgan ... , New York on Tuesday, ... Interested parties are invited to listen to the live audio ... website at www.hologic.com/investors-overview . An archive of the presentation ...
    Breaking Medicine Technology:EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
    ... Conference: February 13-16, 2012 ,Exposition: February ... Organizers of the Medical Design and Manufacturing (MD&M) West ... be held at the Anaheim Convention Center, February 13-16, ... event in the United States dedicated to medical design ...
    ... N.C., Jan. 20, 2012  As the pace of ... has become challenging for the biopharma industry to ... messages. Consumers, key opinion leaders, payers ... and biotech companies reach out to with marketing ...
    Cached Medicine Technology:MD&M West 2012 to Feature Twenty Collocated Conferences 2Utilizing Marketing Innovations to Engage with Customer Groups that are Key to the Pharmaceutical Industry 2
    (Date:9/2/2014)... (HealthDay News) -- Drinking and marijuana may lead to ... study suggests. Researchers analyzed 2007 to 2011 data ... who said they had used alcohol or marijuana at ... was associated with more unsafe driving, damage to relationships ... while under the influence of alcohol, especially among females. ...
    (Date:9/2/2014)... apnea, tonsillectomies, hearing loss, head and neck cancers ... Orlando, FL, September 21-24, at the 2014 Annual ... of OtolaryngologyHead and Neck Surgery Foundation (AAO-HNSF), the ... and neck physicians in the world. , Abstracts ... today, and are available online at http://oto.sagepub.com/content/151/1_suppl ...
    (Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
    (Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
    (Date:9/2/2014)... of Experimental Biology and Medicine that ... biology and medicine of microphysiological systems" and describes ... Systems Program directed by the National Center for ... of Health (NIH) and funded in part by ... Projects Agency (DARPA) and the Food and Drug ...
    Breaking Medicine News(10 mins):Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Microphysiological systems will revolutionize experimental biology and medicine 2Health News:Microphysiological systems will revolutionize experimental biology and medicine 3
    ... , , , ... Sustained reduction of mitral regurgitation following mitral valve repair ... (DMR) or functional mitral regurgitation (FMR) led to heart function ... initial registry cohort of the EVEREST (Endovascular Valve Edge-to-Edge REpair ...
    ... , , , , ... over 2,000 motorcycle riders and enthusiasts will gather at Wisconsin Harley-Davidson ... "Ridin, to a Cure" fund raiser for breast cancer research in ... raise in excess of $300,000 over the weekend. The ride has ...
    ... , , One of Nation,s Best ... The health care network operated by the Department of Veterans Affairs (VA) has ... by the American Association of Retired Persons (AARP). , , "Quality ... Affairs Eric K. Shinseki. "VA is proud to be recognized as a top ...
    ... CHELMSFORD, Mass., Sept. 22 Magellan Biosciences, Inc. (Magellan), ... Life Sciences Tools (LST) business to Sunnyvale, California-based Dionex, Inc. ... ESA,s HPLC-related products, HPLC clinical assays, the ESA Laboratories services ... Financial terms of the transaction were not disclosed. , ...
    ... VA Physical therapist-directed exercise counseling combined with ... and exercise capacity in people with type 2 ... exercise, according to a randomized clinical trial published ... , the scientific journal of the American Physical ...
    ... Mo. About 2 million Americans currently use cocaine ... to making it one of the most dangerous and ... cause severe biological and behavioral problems, is very difficult ... and Sandeep Pendyam, doctoral students in the Department of ...
    Cached Medicine News:Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 2Health News:MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation 3Health News:We Need Your Support - 'Ridin' to a Cure' Sept. 25 and 26 2Health News:VA's Health System Top Employer for AARP 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 2Health News:Magellan Biosciences Sells its Life Sciences Tools Business to Dionex 3Health News:People with type 2 diabetes improved muscular strength 2Health News:Computer model shows changes in brain mechanisms for cocaine addicts 2
    Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
    Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
    ... A sophisticated research tool that allows ... area which is being stimulated. Besides it ... the examiner to switch between the pupil ... computer screen. This system is especially suited ...
    The only air-based esthesiometer with a database of normal sensation on the cornea. May have application to the measurement of normal-tension glaucoma....
    Medicine Products: